Research Topics
| Marcelo BigalSummaryAffiliation: Merck Research Laboratories Country: USA Publications
| Collaborators
|
Detail Information
Publications
Barriers to satisfactory migraine outcomes. What have we learned, where do we stand?Marcelo Bigal
The Merck Research Laboratories, 1 Merck Drive, office WHS 3C26, Whitehouse Station, NJ 08889, USA
Headache 49:1028-41. 2009..We follow by addressing new barriers to migraine care that have emerged as a function of the knowledge gained in this process...
Migraine attacks the Basal GangliaNasim Maleki
Department of Radiology, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA
Mol Pain 7:71. 2011....
Overuse of acute migraine medications and migraine chronificationMarcelo E Bigal
Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
Curr Pain Headache Rep 13:301-7. 2009..While we await randomized trials, these findings should inform the choice of acute migraine treatments with the goal of reducing the risk of migraine progression to chronic migraine...
Putative mechanisms of the relationship between obesity and migraine progressionMarcelo E Bigal
Global Director for Scientific Affairs, Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
Curr Pain Headache Rep 12:207-12. 2008..In addition, we discuss the importance of metabolic syndrome and autonomic dysfunction in modulating the obesity/migraine progression relationship...
Migraine in the triptan era: progresses achieved, lessons learned and future developmentsMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Arq Neuropsiquiatr 67:559-69. 2009..We then review the class of the triptans--mechanism of action and clinical evidence. We close by briefly discussing the class of CGRP receptor antagonists, which is currently being developed for the acute treatment of migraine...
Excessive acute migraine medication use and migraine progressionMarcelo E Bigal
Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
Neurology 71:1821-8. 2008..Accordingly, specific classes of medications are associated with migraine progression, and high frequency of headaches seems to be a risk factor for chronic migraine regardless of medication exposure...
Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraineM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Cephalalgia 29:1188-96. 2009..0 vs. -1.3 mmHg) and high-density lipoprotein cholesterol (-3.7 vs. -0.8 mg/dl). Increased weight during migraine treatment is not associated with poor headache treatment outcomes, but is associated with deterioration of CVD risk markers...
Migraine and cardiovascular disease: possible mechanisms of interactionM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Neurology 72:1864-71. 2009..Ultimately, it will be important to determine whether MA is a modifiable risk factor for CVD and if preventive medications for migraine or antiplatelet therapy might reduce the risk of CVD in patients with MA...
The acute treatment of episodic and chronic migraine in the USAM E Bigal
Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
Cephalalgia 29:891-7. 2009..For CM, > 34% use opiates or barbiturates. Accordingly, a sizable proportion use medications that are not firstline according to the US Headache Consortium Guidelines...
The epidemiology, burden, and comorbidities of migraineMarcelo E Bigal
Merck Research Laboratories, 1 Merck Drive, Whitehouse Station, NJ 08889, USA
Neurol Clin 27:321-34. 2009..For some such as depression, the association has been well described, but for others, the relationship has been recently suggested, such as in the case of clinical and subclinical vascular brain lesions and coronary heart disease...
The triptansMarcelo E Bigal
Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
Expert Rev Neurother 9:649-59. 2009..We close with our view of the future and hopes for the next generation of antimigraine therapies...
Malformations of cortical developmentMarilisa M Guerreiro
Departamento de Neurologia, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, SP, Brasil
Arq Neuropsiquiatr 67:570-4. 2009..The second part of this presentation will address the most important MCD. Finally, the last part of this presentation will address the correlation between MCD and epilepsy...
Clinical course in migraine: conceptualizing migraine transformationMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Neurology 71:848-55. 2008..Herein we discuss the evidence that migraine may transform and then consider potential mechanisms as well as risk factors. We close with a brief discussion of clinical strategies that arise based on this perspective on migraine...
What predicts the change from episodic to chronic migraine?Marcelo E Bigal
Merck Research Laboratories, Merck, Inc, Whitehouse Station, New Jersey, USA
Curr Opin Neurol 22:269-76. 2009..Because migraine worsens in a sizeable subgroup of sufferers, but not in most, identifying factors that predict the change from episodic into chronic migraine is of extreme interest and should be seen as a priority in headache research...
Prevalence and characteristics of allodynia in headache sufferers: a population studyM E Bigal
Departments of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Neurology 70:1525-33. 2008..The authors estimated the prevalence and severity of cutaneous allodynia (CA) in individuals with primary headaches from the general population...
Occipital levels of GABA are related to severe headaches in migraineM E Bigal
Departments of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Neurology 70:2078-80. 2008
The metabolic headachesMarcelo E Bigal
Global Director for Scientific Affairs, Neuroscience, Merck Research Laboratories, One Merck Drive, PO Box 100, Whitehouse Station, NJ 08889, USA
Curr Pain Headache Rep 12:292-5. 2008..For each headache type, we discuss the clinical features and diagnosis, as well as therapeutic strategies...
The paradoxical effects of analgesics and the development of chronic migraineMarcelo E Bigal
Office of the Chief Medical Officer, Merck and Co, Inc, North Wales, PA 19454, USA
Arq Neuropsiquiatr 69:544-51. 2011..The concept of critical dose of exposure for different classes is presented and biological plausibility and putative mechanisms are reviewed...
Migraine and cardiovascular diseaseMarcelo E Bigal
Head of the Merck Investigator Studies Program, Scientific Education Group, Office of the Chief Medical Officer, Merck Inc, Upper Gwynedd, PA, USA
Arq Neuropsiquiatr 69:122-9. 2011..We follow by summarizing the evidence on the topic. We then briefly present the results of a recent meta-analysis. We close by highlighting results of a large epidemiological study conducted after the publication of the meta-analysis...
Migraine chronificationMarcelo E Bigal
Head of the Merck Investigator Study Program and Scientific Education Group, Office of the Chief Medical Officer, Merck and Co, Inc, 351 North Sumneytown Pike, North Wales, PA 19454, USA
Curr Neurol Neurosci Rep 11:139-48. 2011....
Chronic migraine in the population: burden, diagnosis, and satisfaction with treatmentMarcelo E Bigal
Merck Research Laboratories, 1 Merck Drive, Whitehouse Station, NJ 08889, USA
Neurology 71:559-66. 2008..To evaluate the disability profile and patterns of treatment and health care use for chronic migraine (CM) in the general population, in contrast to episodic migraine...
Advances in the pharmacologic treatment of tension-type headacheMarcelo E Bigal
Global Director for Scientific Affairs, Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
Curr Pain Headache Rep 12:442-6. 2008..We close by discussing potential future therapies, including calcitonin gene-related peptide receptor antagonism, as well as substance P and the nitric oxide pathways...
Migraine and cardiovascular disease: a population-based studyM E Bigal
1 Merck Dr, PO Box 100, Whitehouse Station, NJ 08889 0100, USA
Neurology 74:628-35. 2010..Herein we contrast the rate of diagnosed CVD as well as of risk factors for CVD in individuals with migraine with and without aura (MA and MO) and in controls...
A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraineMarcelo Bigal
Merck Research Laboratories, Whitehouse Station, NJ, USA
Headache 48:1286-93. 2008..To assess the efficacy and tolerability of rizatriptan (RI), dexamethasone (DE), and RI combined with DE (RI+DE) in the acute treatment of menstrually related migraine (MRM)...
Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measuresStephen Silberstein
Thomas Jefferson University, Department of Neurology, Philadelphia, PA 19107, USA
Headache 49:1153-62. 2009..To define yet more clearly the utility of topiramate in the treatment of chronic migraine, we evaluated prespecified secondary endpoints from a recent randomized, double-blind, placebo-controlled, multicenter clinical trial...
Key concepts of migraine postdrome: a qualitative study to develop a post-migraine questionnaireDaisy S Ng-Mak
Epidemiology Department, Merck Sharp and Dohme Corp, North Wales, PA 19454, USA
Headache 51:105-17. 2011..To understand migraine postdrome by directly interviewing migraine patients with postdrome symptoms. To document these symptoms, as well as impacts, as a prelude to developing a postdrome migraine questionnaire...
Migraine treatment with rizatriptan and almotriptan: a crossover studyDaisy S Ng-Mak
Epidemiology Department, Merck Research Laboratories, 351 North Sumneytown Pike, North Wales, PA, USA
Headache 49:655-62. 2009..Rizatriptan and almotriptan are effective and well-tolerated triptans that have not been compared directly...
Memantine in the preventive treatment of refractory migraineMarcelo Bigal
Merck Research Laboratories and the Albert Einstein College of Medicine Neurology, Bronx, New York, NY, USA
Headache 48:1337-42. 2008..To assess the efficacy and tolerability of memantine(MEM)in the preventive treatment of refractory migraine...
Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combinationR B Lipton
Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Neurology 63:1099-101. 2004..The headaches were self-limited (69.4% placebo efficacy in 2 hours) and the incidence markedly declined over time. Acetaminophen was no more effective than placebo in the acute and preemptive treatment of these headaches...
Satisfaction with current migraine therapy: experience from 3 centers in US and SwedenMarcelo Bigal
Albert Einstein College of Medicine Neurology, Bronx, NY 10461, USA
Headache 47:475-9. 2007..To assess the level of satisfaction and determinants of satisfaction or dissatisfaction of patients presenting in tertiary care, in regard to their usual care (UC) for the acute treatment of migraine...
Migraine in adolescents: association with socioeconomic status and family historyM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Neurology 69:16-25. 2007..The influence of socioeconomic status on the prevalence of migraine is unknown in adolescents. Accordingly, we investigated the prevalence of migraine in a large sample of adolescents by sociodemographic features...
Prevalence and impact of migraine and probable migraine in a health planN V Patel
AdvancePCS, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Neurology 63:1432-8. 2004..A large number of headache sufferers with features of migraine fail to meet criteria for strict migraine (SM; migraine with or without aura) but do meet criteria for probable migraine (PM)...
Patterns of medical diagnosis and treatment of migraine and probable migraine in a health planM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, NY, USA
Cephalalgia 26:43-9. 2006..Educational strategies should focus on physician education addressing diagnosing the full spectrum of migraine and physician management of migraine with specific migraine therapy in appropriate patients...
Why headache treatment failsR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY10461, USA
Neurology 60:1064-70. 2003..Persistence in treating these patients can be very rewarding. The authors provide a checklist intended to facilitate the management of refractory patients...
Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of lifeR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Neurology 65:S50-8. 2005..We consider clinical trials strategies designed to address the more complex clinical and policy requirements for meeting the needs of those with migraine...
Intravenous dipyrone for the acute treatment of episodic tension-type headache: a randomized, placebo-controlled, double-blind studyM E Bigal
Departmet of Neurology, Albert Einstein School of Medicine, Bronx, NY, USA
Braz J Med Biol Res 35:1139-45. 2002..6%) for the dipyrone group. Intravenous dipyrone is an effective drug for the relief of pain in tension-type headache and its use is justified in the emergency room setting...
Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled studyM E Bigal
Department of Neurology, Sao Paulo University, School of Medicine at Ribeirao Preto, 3900, 14049 900 Ribeirao Preto, SP, Brazil
Cephalalgia 22:345-53. 2002..Our data support the idea that magnesium sulphate can be used for the treatment of all symptoms in migraine with aura, or as an adjuvant therapy for associated symptoms in patients with migraine without aura...
Etiology and distribution of headaches in two Brazilian primary care unitsM E Bigal
Department of Neurology, , , , SP, Brazil
Headache 40:241-7. 2000....
Headache prevention outcome and body mass indexM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Cephalalgia 26:445-50. 2006..Contrary to what we hypothesized, obesity at baseline does not seem to be related to follow-up refractoriness to preventive treatment...
Chronic migraine is an earlier stage of transformed migraine in adultsM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Neurology 65:1556-61. 2005..They are often classified as transformed migraine (TM), a disorder not addressed in the International Headache Society classification...
Epilepsy and migraineM E Bigal
Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Epilepsy Behav 4:S13-24. 2003..We summarize the epidemiologic evidence that migraine and epilepsy are associated and discuss specific interrelationships between migraine and epilepsy...
Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) studyS Silberstein
Jefferson Headache Center, Philadelphia, PA, USA
Cephalalgia 27:220-34. 2007..In contrast to migraine, which is less prevalent in African-Americans than in Whites, PM is more prevalent in African-Americans than in Whites. In the USA, many with PM do not receive adequate treatment...
[Evaluation of placebo use in migraine without aura, migraine with aura and episodic tension-type headache acute attacks]M E Bigal
Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brasil
Arq Neuropsiquiatr 59:552-8. 2001..The mean of this relief, evaluated by the numerical pain scale, was 41.6%, 23.1% and 36%, respectively. Use of placebo is essential in evaluating the therapeutic role of drugs used in the treatment of acute headache...
Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind studyA M Rapoport
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Neurology 69:821-6. 2007..To evaluate the efficacy and tolerability of zolmitriptan 5 mg and 10 mg nasal spray (ZNS) vs placebo in the acute treatment of cluster headache. Design/..
Migraine prevalence, disease burden, and the need for preventive therapyR B Lipton
Department of Neurology, The Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Neurology 68:343-9. 2007....
Field testing alternative criteria for chronic migraineM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Cephalalgia 26:477-82. 2006..Consistently, criteria for CM and CM+ should be revised to require at least 8 days of migraine or probable migraine per month, in individuals with 15 or more days of headache per month...
Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a reviewR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Cephalalgia 24:321-32. 2004....
Migraine practice patterns among neurologistsR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Neurology 62:1926-31. 2004..To assess the attitudes, knowledge, and practice patterns of US neurologists regarding migraine management relative to the US Headache Consortium Guidelines (the Guidelines)...
MMPI personality profiles in patients with primary chronic daily headache: a case-control studyM E Bigal
Department of Neurology, Albert Einstein College of Medicine, Rousso Building, 1165 Morris Park Avenue, Bronx, NY 10461, USA
Neurol Sci 24:103-10. 2003....
Classification of primary headachesR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461 1926, USA
Neurology 63:427-35. 2004..They conclude by presenting an approach to headache diagnosis based upon these criteria...
Primary chronic daily headache and its subtypes in adolescents and adultsM E Bigal
Department of Neurology, Albert Einstein College of Medicine, 1165 Morris Park Avenue, Bronx, NY 10461, USA
Neurology 63:843-7. 2004..To determine the relative frequency of chronic daily headache (CDH) subtypes in adolescents and to compare the distribution of CDH subtypes in adolescents and adults of various ages...
Preventive migraine therapy: what is newA M Rapoport
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
Neurol Sci 25:S177-85. 2004....
Migraine headache disability and health-related quality-of-life: a population-based case-control study from EnglandR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA
Cephalalgia 23:441-50. 2003..Specifically, individuals classified with moderate to severe work-related disability had lower HRQoL scores than those classified with low disability...
Patterns of health care utilization for migraine in England and in the United StatesR B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Neurology 60:441-8. 2003..To assess patterns of medical consultation, diagnosis, and medication use in representative samples of adults with migraine in England and the United States...
New daily persistent headache in the paediatric populationE Kung
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Cephalalgia 29:17-22. 2009..On most days, they had migraine-associated symptoms (one of nausea, photophobia or phonophobia)). NDPH is common in children and adolescents with CDH. Most subjects do not overuse medication. Migraine features are common...
Opioid therapy and headache: a cause and a cureRichard B Lipton
Neurology 62:1662-3. 2004
Cutaneous allodynia in the migraine populationRichard B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Ann Neurol 63:148-58. 2008..To develop and validate a questionnaire for assessing cutaneous allodynia (CA), and to estimate the prevalence and severity of CA in the migraine population...
Tension-type headache: classification and diagnosisMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, 1165 Morris Park Avenue, Bronx, NY 10461, USA
Curr Pain Headache Rep 9:423-9. 2005..A structured approach to the patient and a better comprehension of this variability of presentation should translate into better quality of care and a more specific diagnosis for TTH sufferers...
When migraine progresses: transformed or chronic migraineMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Expert Rev Neurother 6:297-306. 2006..The risk factors for migraine progression and the mechanisms for progression will be discussed. This review concludes with the prospects for treating transformed migraine and avoiding migraine progression...
Looking to the future: research designs for study of headache disease progressionRichard B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Headache 48:58-66. 2008....
Concepts and mechanisms of migraine chronificationMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Headache 48:7-15. 2008..Research on this issue is in its infancy and cautions are necessary before extrapolating this information into clinical practice...
Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraineMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Office 334-A, Rousso Building, 1165 Morris Park Avenue, Bronx, NY 10461, USA
Headache 43:336-42. 2003..The chronicity and pervasiveness of migraine thus is associated with increased functional impairment as well as increase in headache frequency...
Toward an epidemiology of refractory migraine: current knowledge and issues for future researchRichard B Lipton
Departments of Neurology and Epidemiology and Population Health, Albert Einstein College of Medicine, and The Montefiore Headache Center, Bronx, NY, USA
Headache 48:791-8. 2008..The epidemiology of these modifiers is discussed...
Headache as a real diseaseRichard B Lipton
Albert Einstein College of Medicine, Bronx, New York, USA
Headache 48:707-10. 2008..Drs. Lipton and Bigal examine the path to acceptance and the impediments that had to be overcome...
Obesity and chronic daily headacheMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, 1165 Morris Park Avenue, Bronx, NY 10461, USA
Curr Pain Headache Rep 12:56-61. 2008..We then review the potential pathophysiologic mechanisms to support this relationship. We close by briefly discussing clinical interventions related to obesity and migraine...
Obesity, migraine, and chronic migraine: possible mechanisms of interactionMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Neurology 68:1851-61. 2007..Dysfunction in the orexins pathways seems to be a risk factor for both conditions. Finally, conditions that are comorbid to both states (e.g., depression, sleep apnea) may also make the relationship between both diseases more complex...
Tools for diagnosing migraine and measuring its severityRichard B Lipton
Department of Neurology, The Albert Einstein College of Medicine, Bronx, NY, USA
Headache 44:387-98. 2004..Migraine is assessed to determine how well it meets criteria for screening and the steps that are necessary before firm public policy recommendations for screening for migraine are possible...
The medical management of migraineMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
Am J Ther 11:130-40. 2004..The clinicians have in their armamentariums an ever-expanding variety of medications. With experience, clinicians can match individual patient needs with the specific characteristics of a drug to optimize therapeutic benefit...
The epidemiology and impact of migraineMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
Curr Neurol Neurosci Rep 4:98-104. 2004..Probable migraine is a prevalent form of migraine, and like migraine with and without aura it produces decrements in health-related quality of life and increments in disability relative to control subjects...
[Menstrual headache: semiological study in 100 cases]Lineu Miziara
, , , SP, Brasil
Arq Neuropsiquiatr 61:596-600. 2003..Nauseas and/or vomiting were the most frequent associated symptoms. Finally, we found, among the menstrual headaches, 9 cases of tension type headache, 2 cases of cervicogenic headache and 1 case of stabbing headache...
Chronic daily headache: is analgesic overuse a cause or a consequence?Richard B Lipton
Neurology 61:154-5. 2003
The triptan formulations: a critical evaluationMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Arq Neuropsiquiatr 61:313-20. 2003....
Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 casesAlan M Rapoport
Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA
Headache 43:482-9. 2003..CONCLUSIONS: Naratriptan may have a role in the preventive treatment of intractable chronic migraine. Prospective, controlled studies should be considered...
The clinical spectrum of migraineAlan M Rapoport
Columbia University College of Physicians and Surgeons, New York, NY, USA
Compr Ther 29:35-42. 2003..A structured approach to the patient and a better comprehension of this variability of presentation, should translate into better quality of care for migraineurs...
New developments in migraine prophylaxisMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, New York, USA
Expert Opin Pharmacother 4:433-43. 2003..The aim of this review is to present and discuss the new options for migraine prevention...
New migraine preventive options: an update with pathophysiological considerationsMarcelo E Bigal
New England Center for Headache, Stamfor, CT, USA
Rev Hosp Clin Fac Med Sao Paulo 57:293-8. 2002....
Headache and hemodialysis: a prospective studyAna L Antoniazzi
Department of Neurology, , , Brazil
Headache 43:99-102. 2003..CONCLUSIONS: Headache is common in patients undergoing hemodialysis. Classification of such headaches according to the International Headache society criteria may be difficult...
Chronic daily headache: identification of factors associated with induction and transformationMarcelo E Bigal
Department of Neurology and Epidemiology, Albert Einstein College of Medicine, Bronx, New York, USA
Headache 42:575-81. 2002..As similar results were obtained when CPTH was used as a control, the correlation is more complex than simple comorbidity...
Migraine with aura versus migraine without aura: pain intensity and associated symptom intensities after placeboMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA
Headache 42:872-7. 2002..CONCLUSIONS: Our findings suggest that studies comparing placebo against an active drug should use stratification according to the presence versus absence of aura...
Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled studyMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA
Headache 42:862-71. 2002..05 and P<.01) in pain and all associated symptoms compared with control subjects. CONCLUSIONS: Dipyrone is an effective drug for the relief of acute migraine pain and associated symptoms...
[Headache and hemodialysis: evaluation of the possible triggering factors and of the treatment]Ana L Antoniazzi
Departamento de Neurologia, Hospital das Clinicas, Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo, Ribeirao Preto, SP, Brasil
Arq Neuropsiquiatr 60:614-8. 2002..The identification of possible triggering factors and further evaluations of the treatment might increase our knowledge and contribute to reduce the burden of the headaches in patients with chronic renal failure...
Patterns of use of triptans and reasons for switching them in a tertiary care migraine populationFred D Sheftell
Department of Psychiatry, New York Medical College, NY, USA
Headache 44:661-8. 2004..To assess this attributes can provide additional information to supplement the traditional tests of efficacy provided by randomized clinical trials...
Intranasal medications for the treatment of migraine and cluster headacheAlan M Rapoport
Columbia University College of Physicians and Surgeons, New York, NY, USA
CNS Drugs 18:671-85. 2004..Nevertheless, it is our opinion that nasal preparations increase therapeutic options and may result in faster response times and better efficacy than oral formulations and better patient satisfaction than injectable preparations...
Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive casesStewart J Tepper
The New England Center for Headache, Stamford, CT 06902, USA
Headache 44:794-800. 2004..Prospective, controlled studies must be considered for severely disabled, refractory patients...
Ten lessons on the epidemiology of migraineRichard B Lipton
Montefiore Headache Unit, Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Headache 47:S2-9. 2007....
Modifiable risk factors for migraine progression (or for chronic daily headaches)--clinical lessonsMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Headache 46:S144-6. 2006..These recommendations have not been demonstrated to improve outcomes in longitudinal studies...
Obesity is a risk factor for transformed migraine but not chronic tension-type headacheMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Neurology 67:252-7. 2006..To assess the influence of the body mass index (BMI) on the prevalence and severity of chronic daily headache (CDH) and its most frequent subtypes, transformed migraine (TM) and chronic tension-type headache (CTTH)...
Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year periodChelsea A Meskunas
Princeton University, Molecular Biology, NJ, USA
Headache 46:766-72. 2006..Educational initiatives should emphasize that the newer specific acute migraine medications (triptans) may also be associated with PMOH...
Side-locked headache as the chief complaint of inflammatory orbital pseudotumor (myositic form): a case reportAbouch V Krymchantowski
Headache Center of Rio, Rio de Janeiro, Brazil
Headache 46:683-6. 2006..After 5 months she developed orbital and eyelid edema, with painful restrictions to eye movement. Orbital MRI and pathological exam demonstrated inflammatory orbital pseudotumor (myositic form)...
Chronic disorders with episodic manifestations: focus on epilepsy and migraineSheryl R Haut
Comprehensive Epilepsy Management Center, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY 10467 2490, USA
Lancet Neurol 5:148-57. 2006..This investigation draws attention to unique aspects of both epilepsy and migraine, while identifying areas of crossover in which each specialty could benefit from the experience of the other...
Obesity and migraine: a population studyMarcelo E Bigal
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Neurology 66:545-50. 2006..To assess the influence of body mass index (BMI) on the prevalence, attack frequency, and clinical features of migraine...
Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot studyFred D Sheftell
The New England Center for Headache, College of Medicine, Stanford, CT, USA
Headache 45:1400-6. 2005..2) The tolerability of this treatment was excellent. (3) Over a short period of time (3 months), no serious adverse events were reported, nor significant changes were found in the ECG or ophthalmologic evaluation...
Comorbidity of migraineAnn I Scher
Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
Curr Opin Neurol 18:305-10. 2005..Thus, estimates of the burden of migraine often include the costs of conditions comorbid with it...
Zolmitriptan (Zomig)Alan M Rapoport
College of Physicians and Surgeons, Columbia University, New York, NY, USA
Expert Rev Neurother 4:33-41. 2004..5-mg dose at early time points. The physician can now choose the optimum route of delivery of zolmitriptan to stop the headache, increase the likelihood of reducing disability and restore the patient to complete functionality...
The epidemiology of migraineRichard B Lipton
Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
Am J Med 118:3S-10S. 2005..However, prevalence is high in groups other than these high-risk groups. In a subgroup of patients, migraine may be a progressive disorder...
New onset headache in a woman with recurrent ear infectionsBrian M Grosberg
Montefiore Headache Unit, Albert Einstein College of Medicine, Bronx, NY, USA
Headache 45:240-1. 2005
Migraine: epidemiology, impact, and risk factors for progressionRichard B Lipton
Department of Neurology, Albert Einstein College of Medicine and Montefiore Headache Unit, Bronx, NY 10461, USA
Headache 45:S3-S13. 2005..Future epidemiologic studies should focus on identifying patients who are at higher risk for progression and on assessing the impact of intervention strategies on disease progression...
Headache: triumphs in translational researchRichard B Lipton
Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA
Lancet Neurol 4:11-2. 2005
Multiple cranial neuropathies, headache, and facial pain in a septuagenarianBrian M Grosberg
Albert Einstein College of Medicine, The Montefiore Headache Unit, Bronx, NY, USA
Headache 44:1038-9. 2004
[Efficacy of three drugs in the treatment of migrainous aura: a randomized placebo-controlled study]Marcelo E Bigal
, , , SP, Brasil
Arq Neuropsiquiatr 60:406-9. 2002..Our findings make possible some speculations about the pathophysiology of migraine, as well as about the therapeutic approach of patients presenting migrainous aura...
